Skip Navigation

Human Reproduction 2006 21(1):324; doi:10.1093/humrep/dei211
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hannam, T.G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hannam, T.G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Letter to the Editor

‘Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation’

T.G. Hannam

Lifequest Centre for Reproductive Medicine, Toronto, Canada M5G 2K4

E-mail: drhannam@fertility.ca

The first 10% of the full text of this article appears below.

Jan Tesarik et al. (2004)Go set out to improve the implantation rate (IR) in their donor oocyte programme by giving recipients in the study group a single injection of a short-acting GnRH agonist (triptorelin 0.1 . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?